Literature DB >> 28463043

Affinity of human IgG subclasses to mouse Fc gamma receptors.

Gillian Dekkers1, Arthur E H Bentlage1, Tamara C Stegmann1, Heather L Howie2, Suzanne Lissenberg-Thunnissen1, James Zimring2, Theo Rispens3, Gestur Vidarsson1.   

Abstract

Human IgG is the main antibody class used in antibody therapies because of its efficacy and longer half-life, which are completely or partly due to FcγR-mediated functions of the molecules. Preclinical testing in mouse models are frequently performed using human IgG, but no detailed information on binding of human IgG to mouse FcγRs is available. The orthologous mouse and human FcγRs share roughly 60-70% identity, suggesting some incompatibility. Here, we report binding affinities of all mouse and human IgG subclasses to mouse FcγR. Human IgGs bound to mouse FcγR with remarkably similar binding strengths as we know from binding to human ortholog receptors, with relative affinities IgG3>IgG1>IgG4>IgG2 and FcγRI>>FcγRIV>FcγRIII>FcγRIIb. This suggests human IgG subclasses to have similar relative FcγR-mediated biological activities in mice.

Entities:  

Keywords:  Fc-receptors; FcγR; IgG subclasses; mouse models; surface plasmon resonance

Mesh:

Substances:

Year:  2017        PMID: 28463043      PMCID: PMC5524164          DOI: 10.1080/19420862.2017.1323159

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  49 in total

1.  Divergent immunoglobulin g subclass activity through selective Fc receptor binding.

Authors:  Falk Nimmerjahn; Jeffrey V Ravetch
Journal:  Science       Date:  2005-12-02       Impact factor: 47.728

2.  Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation.

Authors:  Yoshikatsu Kaneko; Falk Nimmerjahn; Jeffrey V Ravetch
Journal:  Science       Date:  2006-08-04       Impact factor: 47.728

3.  Mouse model recapitulating human Fcγ receptor structural and functional diversity.

Authors:  Patrick Smith; David J DiLillo; Stylianos Bournazos; Fubin Li; Jeffrey V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-02       Impact factor: 11.205

4.  Intranasal administration of antibody-bound respiratory syncytial virus particles efficiently primes virus-specific immune responses in mice.

Authors:  Debby Kruijsen; Helga K Einarsdottir; Marcel A Schijf; Frank E Coenjaerts; Ellen C van der Schoot; Gestur Vidarsson; Grada M van Bleek
Journal:  J Virol       Date:  2013-05-01       Impact factor: 5.103

5.  Complement is activated by IgG hexamers assembled at the cell surface.

Authors:  Christoph A Diebolder; Frank J Beurskens; Rob N de Jong; Roman I Koning; Kristin Strumane; Margaret A Lindorfer; Marleen Voorhorst; Deniz Ugurlar; Sara Rosati; Albert J R Heck; Jan G J van de Winkel; Ian A Wilson; Abraham J Koster; Ronald P Taylor; Erica Ollmann Saphire; Dennis R Burton; Janine Schuurman; Piet Gros; Paul W H I Parren
Journal:  Science       Date:  2014-03-14       Impact factor: 47.728

6.  Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential.

Authors:  Nigel M Stapleton; Jan Terje Andersen; Annette M Stemerding; Stefania P Bjarnarson; Ruurd C Verheul; Jacoline Gerritsen; Yixian Zhao; Marion Kleijer; Inger Sandlie; Masja de Haas; Ingileif Jonsdottir; C Ellen van der Schoot; Gestur Vidarsson
Journal:  Nat Commun       Date:  2011-12-20       Impact factor: 14.919

Review 7.  Complement System Part I - Molecular Mechanisms of Activation and Regulation.

Authors:  Nicolas S Merle; Sarah Elizabeth Church; Veronique Fremeaux-Bacchi; Lubka T Roumenina
Journal:  Front Immunol       Date:  2015-06-02       Impact factor: 7.561

Review 8.  IgG subclasses and allotypes: from structure to effector functions.

Authors:  Gestur Vidarsson; Gillian Dekkers; Theo Rispens
Journal:  Front Immunol       Date:  2014-10-20       Impact factor: 7.561

9.  Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q.

Authors:  C I Bindon; G Hale; M Brüggemann; H Waldmann
Journal:  J Exp Med       Date:  1988-07-01       Impact factor: 14.307

10.  Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.

Authors:  Tetyana Dashivets; Marco Thomann; Petra Rueger; Alexander Knaupp; Johannes Buchner; Tilman Schlothauer
Journal:  PLoS One       Date:  2015-12-11       Impact factor: 3.240

View more
  66 in total

1.  Single-Cell Intravital Microscopy of Trastuzumab Quantifies Heterogeneous in vivo Kinetics.

Authors:  Ran Li; Adel Attari; Mark Prytyskach; Michelle A Garlin; Ralph Weissleder; Miles A Miller
Journal:  Cytometry A       Date:  2019-08-19       Impact factor: 4.355

2.  Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity.

Authors:  Ugur Eskiocak; Wilson Guzman; Benjamin Wolf; Christine Cummings; Lauren Milling; Hsin-Jung Wu; Michael Ophir; Conner Lambden; Pearl Bakhru; Dana C Gilmore; Samantha Ottinger; Lucy Liu; William K McConaughy; Sunny Q He; Chao Wang; Cheuk Lun Leung; Jason Lajoie; William F Carson; Nora Zizlsperger; Michael M Schmidt; Ana C Anderson; Piotr Bobrowicz; Thomas J Schuetz; Robert Tighe
Journal:  JCI Insight       Date:  2020-03-12

3.  Augmented antibody-based anticancer therapeutics boost neutrophil cytotoxicity.

Authors:  Niels Heemskerk; Mandy Gruijs; A Robin Temming; Marieke H Heineke; Dennis Y Gout; Tessa Hellingman; Cornelis W Tuk; Paula J Winter; Suzanne Lissenberg-Thunnissen; Arthur Eh Bentlage; Marco de Donatis; Marijn Bögels; Thies Rösner; Thomas Valerius; Jantine E Bakema; Gestur Vidarsson; Marjolein van Egmond
Journal:  J Clin Invest       Date:  2021-03-15       Impact factor: 14.808

4.  The Impact of FcγRI Binding on Immuno-PET.

Authors:  Delphine Vivier; Sai Kiran Sharma; Pierre Adumeau; Cindy Rodriguez; Kimberly Fung; Brian M Zeglis
Journal:  J Nucl Med       Date:  2019-02-07       Impact factor: 10.057

5.  Fc-Mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models.

Authors:  Sai Kiran Sharma; Andrew Chow; Sebastien Monette; Delphine Vivier; Jacob Pourat; Kimberly J Edwards; Thomas R Dilling; Dalya Abdel-Atti; Brian M Zeglis; John T Poirier; Jason S Lewis
Journal:  Cancer Res       Date:  2018-01-23       Impact factor: 12.701

Review 6.  Programming Isotype-Specific Plasma Cell Function.

Authors:  Brett W Higgins; Louise J McHeyzer-Williams; Michael G McHeyzer-Williams
Journal:  Trends Immunol       Date:  2019-03-04       Impact factor: 16.687

7.  Suppression of IgE-mediated anaphylaxis and food allergy with monovalent anti-FcεRIα mAbs.

Authors:  Marat V Khodoun; Suzanne C Morris; Wen-Hai Shao; Crystal Potter; Elizabeth Angerman; Artem Kiselev; Alexander E Yarawsky; Andrew B Herr; Katja Klausz; Anna Otte; Matthias Peipp; Fred D Finkelman
Journal:  J Allergy Clin Immunol       Date:  2020-12-14       Impact factor: 10.793

8.  AAV-mediated delivery of actoxumab and bezlotoxumab results in serum and mucosal antibody concentrations that provide protection from C. difficile toxin challenge.

Authors:  Matthew M Guilleman; Brenna A Y Stevens; Laura P Van Lieshout; Amira D Rghei; Yanlong Pei; Lisa A Santry; Brad Thompson; Sarah K Wootton
Journal:  Gene Ther       Date:  2021-02-19       Impact factor: 5.250

Review 9.  The science and medicine of human immunology.

Authors:  Bali Pulendran; Mark M Davis
Journal:  Science       Date:  2020-09-25       Impact factor: 47.728

10.  A perspective on potential antibody-dependent enhancement of SARS-CoV-2.

Authors:  Ann M Arvin; Katja Fink; Michael A Schmid; Andrea Cathcart; Roberto Spreafico; Colin Havenar-Daughton; Antonio Lanzavecchia; Davide Corti; Herbert W Virgin
Journal:  Nature       Date:  2020-07-13       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.